Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells
Open Access
- 20 April 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2885
Abstract
Background: The estrogen receptor (ER) can change expression between primary tumor (PT) and distant metastasis (DM) in breast cancer. A tissue biopsy reflects a momentary state at one location, whereas circulating tumor cells (CTCs) reflect real-time tumor progression. We evaluated ER-status during tumor progression from PT to DM and CTCs, and related the ER-status of CTCs to prognosis. Methods: In a study of metastatic breast cancer, blood was collected at different timepoints. After CellSearch® enrichment, CTCs were captured on DropMount slides and evaluated for ER expression at baseline (BL) and after 1 and 3 months of therapy. Comparison of the ER-status of PT, DM, and CTCs at different timepoints was performed using the McNemar test. The primary endpoint was progression-free survival (PFS). Results: Evidence of a shift from ER positivity to negativity between PT and DM was demonstrated (p = 0.019). We found strong evidence of similar shifts from PT to CTCs at different timepoints (p < 0.0001). ER-positive CTCs at 1 and 3 months were related to better prognosis. Conclusions: A shift in ER-status from PT to DM/CTCs was demonstrated. ER-positive CTCs during systemic therapy might reflect the retention of a favorable phenotype that still responds to therapy.Keywords
Funding Information
- the Swedish Cancer Society (2016/563; 190388)
- The Mrs Berta Kamprad Foundation (2017-39)
- Crafoordska Stiftelsen (20170702)
- Governmental funding of clinical research within the national health service (ALF) (2018-40304)
- Svenska Forskningsrådet Formas (2015-02516)
- Skåne University Hospital Funds (2017-92502; 2018-92502)
- The King Gustav V Jubilee Foundation (19/140141)
- Biocare-strategic research area at Lund University (2016-124359)
This publication has 32 references indexed in Scilit:
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology, 2018
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2015
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2014
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesAnnals of Oncology, 2009
- Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Annals of Oncology, 2009
- Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant TherapyJNCI: Journal of the National Cancer Institute, 2008
- Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast CancerThe Oncologist, 2006
- Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein KinaseJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004